GlassScriptPhysician profile
Ram K Singh
NPI 1891774568
$4,887.26
in general payments reported to CMS, 2019-2025
31 companies · $794 in 2025
The $794 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,089 · 2020: $728 · 2021: $123 · 2022: $58.20 · 2023: $313 · 2024: $781 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $703.52 | 2019-2025 | |
| Amgen INC. | $463.31 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $400.45 | 2019 | |
| Abiomed | $359.76 | 2019-2020 | |
| Pfizer INC. | $324.91 | 2019-2025 | |
| Abbott Laboratories | $322.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $281.85 | 2024-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $277.28 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $246.95 | 2019-2023 | Xarelto |
| Cardiovascular Systems INC. | $246.79 | 2019-2020 | |
| Philips North America LLC | $218.27 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.65 | 2019-2025 | Lifevest |
| Bard Peripheral Vascular, INC. | $178.09 | 2020 | |
| Novo Nordisk INC | $79.78 | 2021-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $74.16 | 2024-2025 | Watchman Flx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $72.36 | 2024 | Arcalyst |
| Cvrx, INC. | $60.01 | 2023-2025 | Barostim Neo System |
| Preventice Services, LLC | $39.97 | 2019 | |
| Bridgebio Pharma, INC. | $35.94 | 2025 | Attruby |
| Amarin Pharma, INC. | $35.12 | 2019 | |
| Edwards Lifesciences Corporation | $28.98 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kestra Medical Technology Services, INC. | $28.70 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $27.63 | 2025 | Amvuttra |
| Ionis Pharmaceuticals, INC. | $26.86 | 2025 | Tryngolza |
| Astrazeneca Pharmaceuticals LP | $23.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $20.64 | 2019 | |
| Irhythm Technologies, INC. | $20.40 | 2021 | |
| Astellas Pharma US INC | $18.46 | 2019 | |
| Chiesi USA, INC. | $16.42 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.